[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.159.27. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 233
Citations 0
Comment & Response
November 2014

Impact of Dietary Benzoic Acid on Treatment Response in Schizophrenia—Reply

Author Affiliations
  • 1Department of Psychiatry, Harbor–UCLA Medical Center, Torrance, California
  • 2Los Angeles Biomedical Research Institute, Harbor–UCLA Medical Center, Torrance, California
JAMA Psychiatry. 2014;71(11):1299. doi:10.1001/jamapsychiatry.2014.709

In Reply While commenting on our article published in JAMA Psychiatry,1 Glue et al raise the issue that “dietary benzoic acid intake may be a significant confounding variable that needs to be considered in interpreting the outcome of this study.” First, the double-blind placebo-controlled design confirmed that the add-on treatment of benzoate is much more efficacious than placebo in improving symptoms and cognition in schizophrenia. It is apparent that both groups had received benzoate from their daily intake of food and drink; however, the active treatment group received a 1000-mg sodium benzoate supplement a day, while the placebo group did not.

First Page Preview View Large
First page PDF preview
First page PDF preview
×